NEW YORK (GenomeWeb News) – Opaldia will distribute DiaGenic’s breast cancer blood test in the UK and will use a research-use-only version of the test in its own studies until the test receives the CE Mark for use in Europe.
 
Opaldia will offer the gene expression test to UK patients under its Breastcare Program. The firm already offers Agendia’s MammaPrint, which is used in disease prognosis, and Agendia's CupPrint, which identifies the origin of metastasized tumors.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

NPR reports that with medical data being big business, some companies want to get patients involved.

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.